COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)

L. Castelo-Branco, Z. Tsourti, S. Gennatas, J. Rogado, M. Sekacheva, D. Viñal, R. Lee, A. Croitoru, M. Vitorino, S. Khallaf, S. Šušnjar, W. Soewoto, A. Cardeña, M. Djerouni, M. Rossi, T. Alonso-Gordoa, C. Ngelangel, J. G. Whisenant, T. K. Choueiri, G. DimopoulouS. Pradervand, D. Arnold, K. Harrington, O. Michielin, U. Dafni, G. Pentheroudakis, S. Peters, E. Romano

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: ESMO COVID-19 and CAncer REgistry (ESMO-CoCARE) is an international collaborative registry-based, cohort study gathering real-world data from Europe, Asia/Oceania and Africa on the natural history, management and outcomes of patients with cancer infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

PATIENTS AND METHODS: ESMO-CoCARE captures information on patients with solid/haematological malignancies, diagnosed with coronavirus disease 2019 (COVID-19). Data collected since June 2020 include demographics, comorbidities, laboratory measurements, cancer characteristics, COVID-19 clinical features, management and outcome. Parameters influencing COVID-19 severity/recovery were investigated as well as factors associated with overall survival (OS) upon SARS-CoV-2 infection.

RESULTS: This analysis includes 1626 patients from 20 countries (87% from 24 European, 7% from 5 North African, 6% from 8 Asian/Oceanian centres), with COVID-19 diagnosis from January 2020 to May 2021. Median age was 64 years, with 52% of female, 57% of cancer stage III/IV and 65% receiving active cancer treatment. Nearly 64% patients required hospitalization due to COVID-19 diagnosis, with 11% receiving intensive care. In multivariable analysis, male sex, older age, Eastern Cooperative Oncology Group (ECOG) performance status ≥2, body mass index (BMI) <25 kg/m 2, presence of comorbidities, symptomatic disease, as well as haematological malignancies, active/progressive cancer, neutrophil-to-lymphocyte ratio (NLR) ≥6 and OnCovid Inflammatory Score ≤40 were associated with COVID-19 severity (i.e. severe/moderate disease requiring hospitalization). About 98% of patients with mild COVID-19 recovered, as opposed to 71% with severe/moderate disease. Advanced cancer stage was an additional adverse prognostic factor for recovery. At data cut-off, and with median follow-up of 3 months, the COVID-19-related death rate was 24.5% (297/1212), with 380 deaths recorded in total. Almost all factors associated with COVID-19 severity, except for BMI and NLR, were also predictive of inferior OS, along with smoking and non-Asian ethnicity.

CONCLUSIONS: Selected patient and cancer characteristics related to sex, ethnicity, poor fitness, comorbidities, inflammation and active malignancy predict for severe/moderate disease and adverse outcomes from COVID-19 in patients with cancer.

Original languageEnglish
Article number100499
JournalESMO Open
Volume7
Issue number3
DOIs
Publication statusPublished - 8 May 2022

Keywords

  • cancer
  • COVID-19
  • oncology
  • SARS-CoV-2
  • Hematologic Neoplasms
  • COVID-19 Testing
  • Humans
  • Middle Aged
  • Male
  • Female
  • Registries
  • Neoplasms/epidemiology
  • Cohort Studies

Fingerprint

Dive into the research topics of 'COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)'. Together they form a unique fingerprint.

Cite this